
PMX-53是一种有效的 C5a 受体拮抗剂,IC50 为 20 nM,具有抗炎,抗癌和抗动脉粥样硬化的活性。PMX-53 也是一种 MrgX2 激动剂,刺激 MrgX2 介导的肥大细胞脱颗粒。



快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解


| 描述 | PMX 53 is a potent C5a receptor antagonist (IC50 = 20 nM). Also MrgX2 agonist, it stimulates MrgX2-mediated mast cell degranulation, also inhibits C5a-induced hypernociception in rats, inhibits lung metastasis in a mouse breast cancer model and reduces atherosclerotic lesions in a mouse model of atherosclerosis. |
| Administration | Dosage | Frequency | Description | References | ||
| Rats | Infantile spasms model | Subcutaneous injection | 0.6 mg/kg | Once daily for 4 days | To evaluate the therapeutic effect of PMX53 on infantile spasms, results showed PMX53 significantly reduced the number of spasms | Sci Rep. 2018 Apr 10;8(1):5722 |
| Rats | Reverse passive Arthus reaction model | Oral, intravenous or topical | 1 – 10 mg/kg | Single dose, 30 min prior (oral) or 10 min prior (intravenous or topical) | Inhibited immune-complex mediated dermal vascular leakage and systemic cytokine production | Br J Pharmacol. 2001 Dec;134(8):1778-86 |
| Mice | MC-38 colorectal cancer model | Intravenous injection | 1 mg/kg | Every other day until the end of the experiment | Evaluated the antitumor effect of PMX-53, demonstrating that PMX-53 suppressed CRC growth by modulating gut microbiota and TLR5/AKT2 pathway to promote M1 polarization. | Cell Death Dis. 2024 Feb 8;15(2):120 |
| Mice | NASH model | Intraperitoneal injection | 1 mg/kg | Every other day for 4 weeks | To evaluate the effect of PMX-53 on liver inflammation and fibrosis in NASH mice | J Gastroenterol. 2023 Sep;58(9):894-907 |
| Mice | Chronic graft-versus-host disease (cGVHD) model | Intraperitoneal injection | 1 mg/kg | Every three days | PMX53 treatment attenuated the pathology of cGVHD, improved the survival rate of mice, and increased the frequency of Treg and expression of TGF-β1 | Sci Rep. 2017 Jun 15;7(1):3603 |
| Mice | K14-HPV16 transgenic mice | Subcutaneous implantation | 1.0 mg/kg/day | Once daily for 28 days | PMX-53 in combination with paclitaxel significantly slowed the growth of squamous cell carcinomas, increased infiltration and cytotoxic properties of CXCR3+ effector memory CD8+ T cells | Cancer Cell. 2018 Oct 8;34(4):561-578. e6 |
| Mice | Bullous pemphigoid model | Intraperitoneal injection | 200 µg/mouse | Daily for 12 days | To evaluate the effect of PMX-53 in prophylactic and therapeutic settings, results showed reduced skin lesions in prophylactic but not therapeutic approach. | Front Immunol. 2018 Mar 15;9:488 |
| Mice | Hind paw incision model | Subcutaneous injection | 30 mcg/paw | 2 hours before surgery and daily 2 hours before behavioral testing | PMX53 reduced incisional mechanical and heat nociceptive sensitization regardless of neutrophil depletion | Anesthesiology. 2012 Sep;117(3):602-12 |
| Mice | Hind paw incisional model | Intraplantar injection | 30 μg/15 μl | Injected 1 hour before incision and then 2 hours before each test session | To evaluate the effect of PMX53 on incision-induced heat hyperalgesia and mechanical allodynia, results showed that PMX53 significantly attenuated heat hyperalgesia and mechanical allodynia induced by hind paw incision | J Neuroinflammation. 2011 Jul 7;8:80 |
| Rats and mice | Mechanical hypernociception model | Intraplantar injection (rats), subcutaneous injection (mice) | 60–180 μg per paw (rats), 0.3–3 mg/kg (mice) | Single administration, observed for 1–24 h | PMX53 inhibited hypernociception induced by zymosan, carrageenan, LPS, and antigen, associated with C5a receptor blockade | Br J Pharmacol. 2008 Mar;153(5):1043-53 |
| 计算器 | ||||
| 存储液制备 | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 1.12mL 0.22mL 0.11mL | 5.58mL 1.12mL 0.56mL | 11.16mL 2.23mL 1.12mL | |
| CAS号 | 219639-75-5 |
| 分子式 | C47H65N11O7 |
| 分子量 | 896.09 |
| SMILES Code | O=C([C@H](CCCNC(N)=N)NC([C@H](CC1=CNC2=CC=CC=C21)NC([C@@H](CC3CCCCC3)NC([C@]4([H])CCCN54)=O)=O)=O)NCCC[C@H](NC([C@@H](NC(C)=O)CC6=CC=CC=C6)=O)C5=O |
| MDL No. | MFCD07363866 |
| 别名 | 3D53 |
| 运输 | 蓝冰 |
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
| 溶解方案 | DMSO: 190 mg/mL(212.03 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 2.5 mg/mL(2.79 mM),配合低频超声,并水浴加热至45℃助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1